Vivet Therapeutics Announces 4 Presentations During the 2022 American Society Of Gene And Cell Therapy Annual Meeting

Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy for rare inherited liver disorders with high unmet medical needs, will present new data from its different programs and platforms during the ASGCT 25th Annual Meeting in Washington DC, May 16 - 18, 2022.

New preclinical data from Vivet Therapeutics’ lead program, VTX-801 for Wilson’s disease, will be disclosed in an oral presentation by Blanche Tamarit. This study further supports the clinical development of VTX-801 in Vivet Therapeutics’ ongoing clinical trial in Wilson’s disease patients (GATEWAY).

During the Immunology session, Vivet will also present new data from one of its technological platforms focusing on the circumvention of neutralizing antibodies, as well as in vitro evaluation of CpG optimization on TLR9 activation.

Vivet Therapeutics’ CSO, Dr. Gloria Gonzalez-Aseguinolaza, will co-chair the “Tools and Approaches for Inborn Errors of Metabolism” session, and will also give an overview of gene therapies for liver diseases in the “Gene Therapy Beyond Cancer” session.

https://annualmeeting.asgct.org/

Oral Presentation:

Title: Safety and Biodistribution of VTX-801, an AAV3B Gene Therapy Vector, in Healthy Cynomolgus Monkeys

Session Title: Pharmacology/Toxicology Studies or Assay Development II / Room 102

Presenter: Blanche Tamarit, Ph.D. – Vivet Therapeutics

Presentation Date and Time: Thursday, May 19, 2022, 11:45 - 12:00 p.m. ET

Poster Presentations:

Title: Optimizing the IdeS Treatment Regimen for Enhanced Adeno-Associated Virus Transduction in the Presence of Neutralizing Antibodies

Session: Immunological Aspects of Gene Therapy and Vaccines II

Presenter: Laia Trigueros Motos, Ph.D. – Vivet Therapeutics

Abstract: 1132

Title: CpG Content Reduction in Codon-Optimized AAV Transgene Sequences Does Not Reduce hTLR9 Activation in an In Vitro Model

Session: Immunological Aspects of Gene Therapy and Vaccines II

Presenter: Nicholas D. Weber, Ph.D. – Vivet Therapeutics

Abstract: 1125

Oral Abstract Sessions:

Session: Tools and Approaches for Inborn Errors of Metabolism / Salon G

Co-chair: Gloria Gonzalez-Aseguinolaza, PhD - Vivet Therapeutics, CSO

Session Date and Time: Monday, May 16, 2022, 3:45 - 5:30 p.m. ET

Session: Gene Therapy Beyond Cancer / Ballroom B

Title: Gene Therapies for Liver Disease

Presenter: Gloria Gonzalez-Aseguinolaza, PhD - Vivet Therapeutics, CSO

Session Date and Time: Wednesday, May 18, 2022, 8:48 - 9:12 a.m. ET